Cencora, Inc. $COR Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp reduced its stake in shares of Cencora, Inc. (NYSE:COR) by 12.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 93,156 shares of the company’s stock after selling 13,319 shares during the period. Van ECK Associates Corp’s holdings in Cencora were worth $29,114,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in Cencora by 13.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after buying an additional 5,543 shares during the period. AustralianSuper Pty Ltd acquired a new stake in shares of Cencora during the 3rd quarter valued at approximately $26,191,000. Mediolanum International Funds Ltd boosted its stake in shares of Cencora by 133.0% during the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after acquiring an additional 32,138 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in shares of Cencora by 40.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after acquiring an additional 4,973 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Cencora by 4.0% in the 3rd quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock worth $134,435,000 after acquiring an additional 16,539 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 0.6%

Shares of NYSE:COR opened at $350.15 on Thursday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The company has a market capitalization of $68.12 billion, a P/E ratio of 42.09, a P/E/G ratio of 1.64 and a beta of 0.68. Cencora, Inc. has a 52-week low of $251.94 and a 52-week high of $377.54. The stock’s fifty day simple moving average is $355.08 and its 200-day simple moving average is $337.60.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter last year, the business posted $3.73 EPS. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 15,220 shares of company stock valued at $5,282,867. Company insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

COR has been the topic of a number of research analyst reports. Evercore decreased their target price on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Barclays lifted their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Finally, Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $399.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.